



SDC INTRODUCES DR. DALE W. USNER AS ITS NEW VICE PRESIDENT OF BIOSTATISTICS

Tempe AZ, September 7, 2011 – Statistics & Data Corporation (SDC) announced today that Dale W. Usner, Ph.D. joined its team as the Vice President of Biostatistics. In his new role, Dr. Usner will be responsible for overseeing the operations of SDC's biostatistics team as well as providing leadership in the continued growth and evolution of SDC as a top-tier provider of biostatistics and data management services.

"We are pleased to welcome Dale Usner to the SDC team as the Vice President of Biostatistics," said Richard B. Abelson, President SDC. "Dale has a deep knowledge of biostatistics, data management, and the entire life sciences industry with tremendous experience across multiple therapeutic areas, including anti-viral and anti-infective, oncology, GI, and ophthalmology. Dale comes to SDC with a proven track record of successfully leading teams for both CROs and Sponsors. I am confident that Dale's focused leadership of our biostatistics team will help to ensure that we continue to exceed our clients' expectations in not just biostatistics but in every aspect of our business."

Prior to joining SDC, Dale served as Director of Biometrics with AVI BioPharma, Inc. in Bothell, WA. Prior to AVI, Dale was with ZymoGenetics, Inc. in Seattle, WA. Before ZymoGenetics, Dale worked for Bausch + Lomb, Inc. in Rochester, NY first as Director of Global Statistics and Data Management and later as a Research Fellow. Prior to Bausch + Lomb, he was with PPD in Wilmington, NC and worked his way up from Statistician to Associate Director in just 3.5 years. Dale's doctorate is in Statistics from Oregon State University. He also holds a Master of Science in Statistics from Carnegie Mellon University and a Bachelor of Science in Mathematics from Dickinson College.

About SDC

SDC delivers leading-edge statistical analysis and data management services to the life sciences industry for pharmaceutical, biotechnology, and medical device companies, as well as CROs. We combine gold standard technology with both deep functional expertise and clinical research experience to provide our clients with total quality assurance, risk mitigation, innovation, and rapid study execution from proof-of-concept through post-approval.